PET/CT in the management of thyroid cancers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24848831.
- Also identified by DOI 10.2214/AJR.13.11673.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thyroid cancer is the most common endocrine cancer. This review evaluates the established use of (18)F-FDG PET/CT in papillary, follicular, Hürthle cell, anaplastic, and medullary thyroid cancers. The significance of incidental diffuse and focal thyroid FDG uptake is discussed. The evolving value of non-FDG radiotracers, including (124)I, (18)F-dihydroxyphenylalanine, and (68)Ga somatostatin analogs, is summarized. PET/CT is a valuable imaging test, in the appropriate clinical context, for the management of thyroid cancers.
Medical subject headings
- Multimodal Imaging
- Positron-Emission Tomography
- Thyroid Neoplasms
- Tomography, X-Ray Computed